Russia's Sputnik-V vaccine equally effective for all age groups: Developer

The Russian-made Sputnik V coronavirus vaccine has proven equally effective for all age groups, Alexander Gintsburg, the head of the Gamaleya research institute that developed the vaccine, said

Sputnik V
Sputnik V. Photo: Reuters
ANI Others
1 min read Last Updated : Mar 14 2021 | 6:37 AM IST

The Russian-made Sputnik V coronavirus vaccine has proven equally effective for all age groups, Alexander Gintsburg, the head of the Gamaleya research institute that developed the vaccine, said on Saturday.

"Sputnik V demonstrated the same level of efficacy in all age groups. At first there were doubts that the efficacy in people aged 60 and over would be lower ... but it was absolutely not," Gintsburg told the SolovyovLive show on YouTube.

The virologist noted that quality-wise Sputnik V beats other COVID-19 vaccines.

"Among those four to six vaccines that have entered mass circulation worldwide, Sputnik V apparently ranks the first in terms of its qualities," Gintsburg noted.

"The effect of this vaccine will be very long. We hope two years and more," the official added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineRussia

First Published: Mar 14 2021 | 6:28 AM IST

Next Story